Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUDJZM)

Drug Name

Dextromethorphan Drug Info

Synonyms

Albutussin; Canfodion; Cosylan; Demorphine; Destrometerfano; Dextromethorfan; Dextromethorphane; Dextromethorphanum; Dextrometorfano; Dextrometorphan; Dextromorphan; Dexyromethorphan; Dormetan; Levomethorphan; Levomethorphane; Levomethorphanum; Levometorfano; Methorphan; RACEMETHORPHAN; Trocal; Balminil DM; Balminil DM Children; Benylin Adult Formula Cough Suppressant; Benylin DM for Children; Benylin Pediatric Cough Suppressant; Delsym Cough Formula; Demorphan hydrobromide; Destrometerfano [DCIT]; Dextromethorfan [Czech]; Dextromethorphan Bromhydrate; Hold DM; Koffex DM; Novahistex DM; Novahistine DM; Pertussin DM Extra Strength; Robitussin Maximum Strength Cough Suppressant; Robitussin Pediatric; Robitussin Pediatric Cough Suppressant; Triaminic DM Long Lasting for Children; BA 2666; Benylin DM 12 Hour; Benylin DM for Children 12 Hour; Sucrets 4 Hour Cough Suppressant; Vicks 44 Cough Relief; Calmylin #1; Cough-X; Creo-Terpin; D-Methorphan; Delta-Methorphan; Dextromethorphan (USP); Dextromethorphane [INN-French]; Dextromethorphanum [INN-Latin]; Dextrometorfano [INN-Spanish]; Diabe-Tuss DM Syrup; Hihustan M.; L-Methorphan; Levomethorphane [INN-French]; Levomethorphanum [INN-Latin]; Levometorfano [INN-Spanish]; Neurodex (TN); Pertussin CS Children's Strength; Romilar (TN); Dextromethorphan [USP:INN:BAN]; Levomethorphan [BAN:DCF:INN]; Levomethorphan [INN:BAN:DCF]; Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)-(9CI); Cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren; (+)-3-Methoxy-17-methylmorphinan; (-)-3-Methoxy-N-methylmorphinan; (9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan; 3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan; 3-Methoxy-17-methylmorphinan; 3-Methoxy-N-methylmorphinon; 9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl-(8CI)

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1]
Common cold	CA00	Approved	[1]
Cough	MD12	Approved	[2]
Fever	MG26	Approved	[1]
Headache	8A80-8A84	Approved	[1]
Rhinitis	FA20	Approved	[1]
Vasomotor/allergic rhinitis	CA08	Approved	[1]

Therapeutic Class

Analgesics

Cross-matching ID

PubChem CID: 5360696
ChEBI ID: CHEBI:4470
CAS Number: CAS 125-71-3
TTD Drug ID: DMUDJZM
VARIDT Drug ID: DR00891
INTEDE Drug ID: DR0476
ACDINA Drug ID: D00177

Molecule-Related Drug Atlas

Molecule Type:

DTT

DME

DOT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Opioid receptor sigma 1 (OPRS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dextromethorphan Polistirex	DMEHCY5	Dry cough	MD12	Approved	[17]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[18]
AVP-786	DMV1SOR	Alzheimer disease	8A20	Phase 3	[19]
ADX N05	DMLBYRA	Mood disorder	6A60-6E23	Phase 3	[20]
Igmesine	DMH97XA	Major depressive disorder	6A70.3	Phase 2	[21]
OPC-14523	DMB1WF3	Bulimia nervosa	6B81	Phase 2	[22]
ANAVEX 2-73	DM67OU4	Alzheimer disease	8A20	Phase 1	[23]
SSR-125047	DMSUFW6	Schizophrenia	6A20	Phase 1	[24]
SA-5845	DM6XZRL	Central nervous system disease	8A04-8D87	Phase 1	[25]
SSR-125329A	DMG6NI8	Immune System disease	4A01-4B41	Phase 1	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[27]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[28]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[29]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[30]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[31]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[32]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[33]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[34]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[28]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[35]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[83]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[84]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[85]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[86]
Proguanil	DMBL79I	Malaria	1F40-1F45	Approved	[87]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[87]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[88]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[89]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[90]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[91]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[36]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[37]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[38]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[31]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[35]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[39]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[40]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[41]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[42]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[43]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[103]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[104]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[105]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[106]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[107]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[108]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[109]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[87]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[110]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[111]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[44]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[45]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[46]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[47]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[48]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[49]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[50]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[51]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[52]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[47]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[83]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[84]
Nelfinavir mesylate	DMFX6G8	N. A.	N. A.	Approved	[89]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[89]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[92]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[93]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[94]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[95]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[96]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[97]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[53]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[47]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[47]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[47]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[7]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[54]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[47]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[47]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[47]
Metronidazole	DMTIVEN	Abscess		Approved	[55]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[56]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[57]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[58]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[7]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[59]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[7]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[60]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[61]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[62]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[63]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2B6 (CYP2B6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[64]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[7]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[65]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[58]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[66]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[67]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[68]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[69]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[70]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[71]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[72]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[56]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[73]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[74]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[7]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[75]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[63]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[77]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[78]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cholesterol 24-hydroxylase (CYP46A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[10]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[10]
Testosterone cypionate	DMC1TEV	N. A.	N. A.	Approved	[10]
ANW-32821	DMMJOZD	N. A.	N. A.	Phase 2	[79]
Phenacetin	DMRQAM0	Analgesia	MB40.8	Withdrawn from market	[10]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[10]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[10]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[95]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[99]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[10]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[100]
ANW-32821	DMMJOZD	N. A.	N. A.	Phase 2	[10]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[101]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[102]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 Drug(s)

Drug(s) Metabolized By Cytochrome P450 102A1 (cyp102)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[11]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[80]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[81]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[82]
Chlorzoxazone	DMCYVDT	Acute pain	MG31	Approved	[82]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[11]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[11]
Mefenamic acid	DMK7HFI	Dysmenorrhea	GA34.3	Approved	[80]
Meclofenamic acid	DM05FXR	Ankylosing spondylitis	FA92.0	Approved	[80]
GEA-6414	DM8J0MK	N. A.	N. A.	Phase 1/2	[80]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[112]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[113]
Fructose	DM43AN2	Vomiting	MD90	Approved	[114]
Ketoprofen	DMRKXPT	Bursitis		Approved	[114]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[115]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[116]
Baclofen	DM0QV1J	Multiple sclerosis	8A40	Approved	[117]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[118]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[119]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[120]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Beta-hexosaminidase subunit beta (HEXB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[121]
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[122]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[123]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[124]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[125]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[126]
Gamolenic acid	DMQN30Z	Allergy	4A80-4A85	Approved	[127]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[128]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[129]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[130]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Interleukin-8 (CXCL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[131]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[132]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[133]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[134]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[135]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[136]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[137]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[138]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[139]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[137]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By C-C motif chemokine 2 (CCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[140]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[141]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[142]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[120]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[143]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[144]
TECFIDERA	DM2OVDT	Multiple sclerosis	8A40	Approved	[145]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[146]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[147]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[148]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[149]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[150]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[151]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[152]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[152]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[153]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[154]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[155]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[156]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[152]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Mas-related G-protein coupled receptor member X2 (MRGPRX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[146]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[130]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[157]
------------------------------------------------------------------------------------

Drug(s) Affected By Arylamine N-acetyltransferase 2 (NAT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[158]
Hydralazine	DMU8JGH	Chronic heart failure	BD1Z	Approved	[159]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[160]
Sulfamethoxazole	DMB08GE	Acute otitis media	AB00	Approved	[161]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[162]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[163]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[164]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[165]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[95]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[166]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[167]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[167]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[167]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[109]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[168]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[169]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[170]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[171]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[172]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[114]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor sigma 1 (OPRS1)	TT5TPI6	SGMR1_HUMAN	Agonist	[3]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)^{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 2D6 (CYP2D6)^{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[5]
Cytochrome P450 2C9 (CYP2C9)^{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[6]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[6]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[7]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[8]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[9]
Cholesterol 24-hydroxylase (CYP46A1)	DEKP5HX	CP46A_HUMAN	Substrate	[10]
Cytochrome P450 102A1 (cyp102)	DE4OGUF	CPXB_BACMB	Substrate	[11]
Cytochrome P450 130A1 (cyp130)	DE6CQ0I	CP130_MYCTU	Substrate	[12]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Arylamine N-acetyltransferase 2 (NAT2)	OTBPDQOY	ARY2_HUMAN	Regulation of Drug Effects	[13]
Beta-hexosaminidase subunit beta (HEXB)	OTROYLCR	HEXB_HUMAN	Protein Interaction/Cellular Processes	[14]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Protein Interaction/Cellular Processes	[14]
Cholesterol 24-hydroxylase (CYP46A1)	OTJ27FOX	CP46A_HUMAN	Biotransformations	[10]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Regulation of Drug Effects	[13]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[15]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Biotransformations	[16]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Biotransformations	[16]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Protein Interaction/Cellular Processes	[14]
Mas-related G-protein coupled receptor member X2 (MRGPRX2)	OT2XA799	MRGX2_HUMAN	Protein Interaction/Cellular Processes	[14]

------------------------------------------------------------------------------------

References

1	Dextromethorphan FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6953).
3	Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7.
4	Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov;29(11):1514-20.
5	Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
6	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004.
7	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
8	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
9	Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994 Jul 5;48(1):173-82.
10	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92.
11	The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
12	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614.
13	Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol. 2004 Jul;44(7):708-14. doi: 10.1177/0091270004266624.
14	Dextromethorphan - A widely-used cough suppressant - Induces local anaphylaxis via MRGPRX2 on mast cells. Chem Biol Interact. 2020 Oct 1;330:109248. doi: 10.1016/j.cbi.2020.109248. Epub 2020 Aug 29.
15	Myoclonus after dextromethorphan administration in peritoneal dialysis. Ann Pharmacother. 2011 Jan;45(1):e1. doi: 10.1345/aph.1P301. Epub 2010 Dec 14.
16	Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos. 2004 Dec;32(12):1434-45. doi: 10.1124/dmd.104.001313. Epub 2004 Sep 21.
17	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
18	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
19	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
20	Clinical pipeline report, company report or official report of SK BioPhamaceuticals.
21	Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19.
22	Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88.
23	2011 Pipeline of Anavex.
24	The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
25	Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45.
26	SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties. Eur J Pharmacol. 2002 Dec 5;456(1-3):123-31.
27	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
28	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
29	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
30	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
31	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
32	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
33	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
34	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
35	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
36	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
37	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
38	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
39	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
40	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
41	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
42	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
43	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
44	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
45	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
46	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
47	Drug Interactions Flockhart Table
48	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
49	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
50	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
51	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
52	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
53	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
54	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
55	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
56	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
57	Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
58	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
59	Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
60	Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
61	New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
62	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
63	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
64	Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
65	Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
66	Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
67	Drugs that may have potential CYP2B6 interactions.
68	Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
69	Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
70	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
71	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
72	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
73	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
74	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
75	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
76	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
77	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
78	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
79	Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos. 2006 Apr;34(4):513-20.
80	Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753.
81	acillus megaterium SF185 spores exert protective effects against oxidative stress in vivo and in vitro. Sci Rep. 2019 Aug 19;9(1):12082.
82	Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
83	The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
84	Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
85	Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
86	The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
87	Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
88	Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
89	Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
90	Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
91	Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
92	Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab Dispos. 2005 Jul;33(7):1074-81. doi: 10.1124/dmd.104.002279. Epub 2005 Apr 8.
93	Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):86-96.
94	Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity. J Toxicol Sci. 2017;42(3):343-348.
95	Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
96	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
97	Induction of hepatic CYP3A enzymes by pregnancy-related hormones: studies in human hepatocytes and hepatic cell lines. Drug Metab Dispos. 2013 Feb;41(2):281-90.
98	Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
99	Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
100	The molecular basis of genistein-induced mitotic arrest and exit of self-renewal in embryonal carcinoma and primary cancer cell lines. BMC Med Genomics. 2008 Oct 10;1:49.
101	Effect of aflatoxin B(1), benzo[a]pyrene, and methapyrilene on transcriptomic and epigenetic alterations in human liver HepaRG cells. Food Chem Toxicol. 2018 Nov;121:214-223. doi: 10.1016/j.fct.2018.08.034. Epub 2018 Aug 26.
102	Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
103	Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
104	Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
105	Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
106	Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
107	Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
108	Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
109	Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
110	Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
111	Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
112	Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
113	A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. Toxicol Appl Pharmacol. 2017 Nov 1;334:18-23. doi: 10.1016/j.taap.2017.08.017. Epub 2017 Sep 1.
114	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
115	CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
116	Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
117	Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
118	Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
119	Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
120	Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
121	Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
122	Crystal structure of -hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone. J Med Chem. 2011 Mar 10;54(5):1421-9. doi: 10.1021/jm101443u. Epub 2011 Jan 25.
123	Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
124	The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
125	Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
126	Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
127	Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr. 2010 Jul;47(1):81-90.
128	Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
129	Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
130	Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
131	Monomeric and oligomeric flavanols maintain the endogenous glucocorticoid response in human macrophages in pro-oxidant conditions in vitro. Chem Biol Interact. 2018 Aug 1;291:237-244.
132	Nicotine up-regulates IL-8 expression in human gingival epithelial cells following stimulation with IL-1 or P. gingivalis lipopolysaccharide via nicotinic acetylcholine receptor signalling. Arch Oral Biol. 2012 May;57(5):483-90. doi: 10.1016/j.archoralbio.2011.10.007. Epub 2011 Nov 25.
133	Ca(2+) Signaling and IL-8 Secretion in Human Testicular Peritubular Cells Involve the Cation Channel TRPV2. Int J Mol Sci. 2018 Sep 19;19(9):2829. doi: 10.3390/ijms19092829.
134	Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
135	Nitrogen mustard prevents transport of Fra-1 into the nucleus to promote c-Fos- and FosB-dependent IL-8 induction in injured mouse epidermis. Toxicol Lett. 2020 Feb 1;319:256-263. doi: 10.1016/j.toxlet.2019.10.006. Epub 2019 Oct 19.
136	ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
137	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
138	Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
139	Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. Am J Respir Crit Care Med. 2000 Jan;161(1):249-56. doi: 10.1164/ajrccm.161.1.9804096.
140	Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
141	Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
142	Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib. Toxicol Lett. 2021 Mar 1;338:1-9. doi: 10.1016/j.toxlet.2020.11.011. Epub 2020 Nov 25.
143	Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
144	Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
145	Dimethyl Fumarate Inhibits the Nuclear Factor B Pathway in Breast Cancer Cells by Covalent Modification of p65 Protein. J Biol Chem. 2016 Feb 12;291(7):3639-47. doi: 10.1074/jbc.M115.679704. Epub 2015 Dec 18.
146	The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
147	Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
148	Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFB and AhR and EGFR-ERK pathway. Toxicol Appl Pharmacol. 2011 Sep 1;255(2):138-49.
149	Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
150	Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
151	Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
152	Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
153	Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
154	Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
155	Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
156	Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
157	Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
158	Interindividual variability in 5-Fluorouracil metabolism and procainamide N-acetylation in human liver cytosol. Biol Pharm Bull. 2005 Jun;28(6):1071-4. doi: 10.1248/bpb.28.1071.
159	Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening. Biochem Pharmacol. 2005 Jan 15;69(2):347-59. doi: 10.1016/j.bcp.2004.09.014. Epub 2004 Nov 24.
160	Association analysis of N-acetyl transferase-2 polymorphisms with aspirin intolerance among asthmatics. Pharmacogenomics. 2010 Jul;11(7):951-8. doi: 10.2217/pgs.10.65.
161	Analysis of nucleotide diversity of NAT2 coding region reveals homogeneity across Native American populations and high intra-population diversity. Pharmacogenomics J. 2007 Apr;7(2):144-52. doi: 10.1038/sj.tpj.6500407. Epub 2006 Jul 18.
162	The xenobiotic-metabolizing enzymes arylamine N-acetyltransferases in human lens epithelial cells: inactivation by cellular oxidants and UVB-induced oxidative stress. Mol Pharmacol. 2005 Apr;67(4):1299-306.
163	Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers. Clin Exp Pharmacol Physiol. 2009 Aug;36(8):828-33.
164	Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
165	Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
166	From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
167	In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
168	Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
169	Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
170	Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
171	Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
172	Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.